Author:
Sanghavi Nirali,Farwa Umme,Khurshid Faisal,Husain Hatim
Publisher
Springer International Publishing
Reference45 articles.
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Ada G. The coming of age of tumour immunotherapy. Immunol Cell Biol. 1999;77(2):180–5.
3. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.
4. JM TR, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression. Sem Cancer Biol. 2009;17(4):275–87.
5. Page DB, Bourla AB, Daniyan A, Naidoo J, Smith E, Smith M, et al. Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer. J Immunother Cancer. 2015;3(1):1–10.